

1623
Cru

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Confirmation No.: 5103

von BORSTEL et al.

Atty. Ref.: 1331-138

Appln. No. 08/460,186

T.C. / Art Unit: 1623

Filed: June 2, 1996

Examiner: Owens, H.

For: TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT
TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES

* * * * *

INFORMATION DISCLOSURE STATEMENT

February 25, 2005

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a Form PTO-1449 listing the documents relied upon by Applicants in their arguments filed as a First Submission under Rule 129(a) on February 23, 2005 as well as U.S. patents disclosing compounds similar to those disclosed in this application.

This Information Disclosure Statement (IDS) is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search


has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



Gary R. Tanigawa
Reg. No. 43,180

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

APPLN. NO.

ATTY. DKT. NO.

08/460,186

1331-138

APPLICANT

VON BORSTEL et al.

FILING DATE

GROUP

June 2, 1995

1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR	5,246,708	09/1993	von Borstel et al.			
BR	5,470,838	11/1995	von Borstel et al.			
CR	5,583,117	12/1996	von Borstel et al.			
DR	5,691,320	11/1997	von Borstel et al.			
ER	5,736,531	04/1998	von Borstel et al.			
FR	5,770,582	06/1998	von Borstel et al.			
GR	5,968,914	10/1999	von Borstel et al.			
HR	6,020,320	02/2000	von Borstel et al.			
IR	6,020,322	02/2000	von Borstel et al.			
JR	6,054,441	04/2000	von Borstel et al.			
KR	6,060,459	05/2000	von Borstel et al.			
LR	6,103,701	08/2000	von Borstel et al.			
MR	6,232,298	05/2001	von Borstel et al.			
NR	6,255,290	07/2001	von Borstel et al.			
OR	6,258,795	07/2001	von Borstel et al.			
PR	6,274,563	08/2001	von Borstel et al.			
QR	6,297,222	10/2001	von Borstel et al.			
RR	6,306,834	10/2001	von Borstel et al.			
SR	6,316,426	11/2001	von Borstel et al.			
TR	6,329,350	12/2001	von Borstel et al.			
UR	6,344,447	02/2002	von Borstel et al.			
VR	6,348,451	02/2002	von Borstel et al.			
WR	6,403,565	06/2002	von Borstel et al.			
XR	6,417,170	07/2002	von Borstel et al.			
YR	6,465,440	10/2002	von Borstel et al.			
ZR	6,472,378	10/2002	von Borstel et al.			
AAR	6,743,782	06/2004	von Borstel et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
BBR					
CCR					

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

DDR	Kelsen et al. "Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer" J. Clin. Oncol. 15:1511-1517 (1997)
EER	Peters et al. "In vitro biochemical and in vivo biologicals studies of the uridine 'rescue' of 5-fluorouracil" Brit. J. Cancer 57:259-265 (1988)
FFR	
GGR	

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)